Zhang Wei, Shao Zonghong, Fu Rong, Wang Huaquan, Li Lijuan, Yue Lanzhu
Department of Hematology, General Hospital of Tianjin Medical University, Tianjin 300052, P.R. China.
Oncol Lett. 2013 Jul;6(1):203-206. doi: 10.3892/ol.2013.1346. Epub 2013 May 14.
The myelodysplastic syndromes (MDSs) are a group of clonal stem cell disorders resulting from aberrations within hematopoietic stem cells (HSCs), which may lead to the onset of a number of diseases, including acute myeloid leukemia (AML). Recent studies have demonstrated that the expression levels of the DLK1 gene are increased in MDS. In order to determine whether the addition of DLK1 affects tumorigenesis, small interfering (si)RNAs were designed to target DLK1 in order to knockdown its expression in CD34CD38 bone marrow cells in MDS. A lower proliferative rate was observed in the CD34CD38 bone marrow cells following this knockdown of DLK1 expression. The suppression of DLK1 expression resulted in a less aggressive MDS phenotype, which suggests that the upregulation of DLK1 expression may play an oncogenic role in CD34+CD38 bone marrow cells.
骨髓增生异常综合征（MDS）是一组由造血干细胞（HSC）畸变引起的克隆性干细胞疾病，可能导致多种疾病的发生，包括急性髓系白血病（AML）。最近的研究表明，MDS中DLK1基因的表达水平升高。为了确定DLK1的添加是否影响肿瘤发生，设计了小干扰（si）RNA靶向DLK1，以敲低其在MDS患者CD34⁺CD38⁻骨髓细胞中的表达。DLK1表达敲低后，CD34⁺CD38⁻骨髓细胞的增殖率降低。DLK1表达的抑制导致MDS表型的侵袭性降低，这表明DLK1表达的上调可能在CD34⁺CD38⁻骨髓细胞中发挥致癌作用。
